Which of the following is true about the novel antiviral drug Remdesivir?

Remdesivir Novel antiviral agent developed by Gilead Sciences First developed as an antiviral against Ebola virus during the 2014 outbreak in west Africa. Adenosine analog Interferes with the action of the viral RNA dependent RNA polymerase Evades proof reading by the viral exoribonuclease causing decrease in viral RNA production. Promising results in animal studies for MERS-CoV and SARS, suggesting it may have some effects in patients with COVID-19. Dose being studied is 200mg iv on day one followed by 100mg iv once daily for 4 to 9 days. Currently Remdesivir has received investigational new drug (IND) status and several clinical trials are ongoing on patients with SARS-CoV-2 infection.